{"disease":{"id":"ovarian-cancer-epithelial","name":"ovarian cancer epithelial"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05116189","title":"Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":643,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05870748","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":600,"lead_sponsor_name":"Sutro Biopharma, Inc.","has_results":false},{"nct_id":"NCT01891344","title":"A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":491,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT02855944","title":"ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":349,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04473339","title":"A Randomized Prospective Trail of HIPEC in Recurrent Ovarian Cancer Patients With HRR Mutation","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":280,"lead_sponsor_name":"CAI Hongbing","has_results":false},{"nct_id":"NCT01286987","title":"Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":113,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03371693","title":"Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":112,"lead_sponsor_name":"Zhongnan Hospital","has_results":false},{"nct_id":"NCT02122185","title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":111,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT04244552","title":"A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":87,"lead_sponsor_name":"Atreca, Inc.","has_results":false},{"nct_id":"NCT05483933","title":"Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Shattuck Labs, Inc.","has_results":true},{"nct_id":"NCT05001282","title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":79,"lead_sponsor_name":"Elucida Oncology","has_results":false},{"nct_id":"NCT06640348","title":"Ultrasensitive SERS Platform With Highly Efficient Enrichment of Analyte for Screening and Diagnosis of Epithelial Ovarian Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Anhui Provincial Hospital","has_results":false},{"nct_id":"NCT04566952","title":"Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Xiaoxiang Chen","has_results":false},{"nct_id":"NCT04537702","title":"Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05585034","title":"Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT07460180","title":"The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT00795769","title":"Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT03311334","title":"A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":true},{"nct_id":"NCT04402333","title":"Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT03742388","title":"A Genomic Analysis of Evolution of Epithelia Ovarian Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Lei Li","has_results":false},{"nct_id":"NCT05429970","title":"A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04676334","title":"CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT07117877","title":"Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT05498597","title":"AMT-151 in Patients With Selected Advanced Solid Tumours","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Multitude Therapeutics Inc.","has_results":false},{"nct_id":"NCT02135523","title":"The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT01322802","title":"Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT03321188","title":"Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Andrea Jewell","has_results":false},{"nct_id":"NCT05856409","title":"Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05960630","title":"MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Royal Surrey County Hospital NHS Foundation Trust","has_results":false},{"nct_id":"NCT05422183","title":"Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Zhongda Hospital","has_results":false},{"nct_id":"NCT02082470","title":"Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT05261490","title":"Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05335993","title":"A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"CanariaBio Inc.","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT04415944","title":"Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT01536054","title":"Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":7,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}